medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Evaluating the Long-Term Efficacy of COVID-19 Vaccines
Dan-Yu Lin,1 Donglin Zeng,1 and Peter B. Gilbert2
1. Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA;
2. Vaccine and Infectious Disease Division, Fred Hutch, Seattle, Washington, USA

Summary: We show how to estimate potentially waning long-term efficacy of COVID19 vaccines in randomized, placebo-controlled clinical trials with staggered enrollment of
participants and sequential crossover of placebo recipients.
Abstract: Large-scale deployment of safe and durably effective vaccines can halt the
COVID-19 pandemic.1âˆ’3 However, the high vaccine efficacy reported by ongoing phase 3
placebo-controlled clinical trials is based on a median follow-up time of only about two
months4âˆ’5 and thus does not pertain to long-term efficacy. To evaluate the duration of protection while allowing trial participants timely access to efficacious vaccine, investigators can
sequentially cross placebo recipients to the vaccine arm according to priority groups. Here,
we show how to estimate potentially time-varying placebo-controlled vaccine efficacy in this
type of staggered vaccination of placebo recipients. In addition, we compare the performance
of blinded and unblinded crossover designs in estimating long-term vaccine efficacy.
Keywords: booster vaccination; durability of vaccine efficacy; phase 3 trials; SARS-CoV-2;
severe COVID-19; waning efficacy
Authorsâ€™ Information: Dan-Yu Lin, Ph.D., is Dennis Gillings Distinguished Professor of
Biostatistics, and Donglin Zeng, Ph.D., is Professor of Biostatistics, Gillings School of Global
Public Health, University of North Carolina, Chapel Hill, NC 27599-7420, USA. Peter B.
Gilbert, Ph.D., is Member, Vaccine and Infectious Disease Division, Fred Hutch, Seattle,
WA 98109-1024, USA.
Correspondence: Dan-Yu Lin, PhD, Department of Biostatistics, University of North
Carolina, Chapel Hill, NC 27599-7420, USA (lin@bios.unc.edu).
1

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Introduction
A number of studies have been conducted around the world to evaluate the efficacy and safety
of investigational vaccines against novel coronavirus disease-2019 (COVID-19).4âˆ’12 Interim
results from several large-scale phase 3 randomized, observer-blinded, placebo-controlled
clinical trials have demonstrated high vaccine efficacy,4âˆ’6 far exceeding the FDA and WHO
thresholds of 50% reduction of symptomatic disease.13âˆ’14 However, those trials have been
underway for only several months, and the data they have collected thus far can only speak
to short-term vaccine efficacy. For example, the interim results for the Pfizer/BioNTech
vaccine BNT162b2 and the Moderna vaccine mRNA-1273 that were presented for regulatory
approval are based on a median follow-up time of approximately two months after the second
dose;4âˆ’5 therefore, the reported 94-95% efficacy pertains only to an average of two months
post vaccination.
Vaccine efficacy can wane over time because of declining immunologic memory or changing antigenicity of the pathogen. Thus, it is critically important to determine the duration
of protection and the need for additional booster doses of vaccine. Certainly, after FDA
issues Emergency Use Authorization (EUA), vaccine sponsors should continue to collect
placebo-controlled data in any ongoing trials for as long as feasible.15
Although continuing blinded follow-up of the original treatment arms offers the ideal
opportunity to evaluate long-term vaccine efficacy and safety, placebo recipients should be
offered the vaccine at some point after an EUA. One strategy is the â€œrolling crossoverâ€,
which vaccinates placebo recipients around the same time as general population members
in the same priority tier. Under this design, placebo participants are vaccinated at different
times, with the timing of vaccination depending on enrollment characteristics that define
their priority tier.
In this article, we show how to evaluate long-term vaccine efficacy under the rolling
crossover design. Because of staggered enrollment, existing statistical methods do not produce valid estimates of time-varying vaccine efficacy even if the placebo group is maintained

2

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

throughout the study. Our approach properly accounts for staggered enrollment and change
of background incidence over time, as well as for the fact that higher-risk placebo volunteers
may get vaccinated earlier than lower-risk ones during the crossover period. It provides
unbiased estimation of the entire curve of placebo-controlled vaccine efficacy as a function
of time elapsed since vaccination, up to the point where most of the placebo recipients have
crossed over to the vaccine arm. We investigate the bias and precision in estimating longterm vaccine efficacy under various blinded and unblinded crossover designs and discuss how
to perform sensitivity analysis when unblinded follow-up data are used.
Methods
Figure 1 provides a schematic illustration of the rolling crossover strategy in the context of
the two mRNA vaccine trials. In this scenario, participants were screened and randomly
assigned to vaccine or placebo over a 4-month period, and the vaccine was approved in the
5th month on the basis of interim results. Under the proposed design, crossover based on
priority groups will occur over the next five months.
The endpoint of interest is time to symptomatic COVID-19 disease. We allow the background risk of disease to vary over the calendar time and to depend on baseline risk factors,
such as age, gender, ethnicity, race, occupation, and underlying health conditions. In addition, we allow the relative risk of disease for vaccine versus placebo to depend on the duration
elapsed since vaccination. We define the Ï„ -day vaccine efficacy as the percentage reduction
in the cumulative incidence of disease over the Ï„ -day period for those who were vaccinated
at the start of the Ï„ -day period versus those who have not been vaccinated by day Ï„ .
In Supplemental Appendix 1, we formulate the above framework through an adaptation
of the popular Cox proportional hazards model16âˆ’17 and derive the maximum likelihood
estimator for the curve of placebo-controlled vaccine efficacy as a function of time elapsed
since vaccination. In addition, we show that the estimator is approximately unbiased and
normally distributed, with a variance that can be estimated analytically, making it possible
to construct valid confidence intervals for the vaccine-efficacy curve.
3

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Results
We conducted a series of simulation studies mimicking the BNT162b2 vaccine trial. We
considered 40,000 participants, who entered the trial at a constant rate over a 4-month period
and were randomly assigned to vaccine or placebo in a 1:1 ratio. The vaccine received an
EUA from FDA at the 5th month, by which time there were about 300 COVID-19 cases
in the placebo group. To reflect the increase of COVID-19 cases since last summer and the
expected downward trend in the spring due to herd immunity, we let the disease risk increase
over the first 7 months and decrease afterward. We set the vaccine efficacy at 5 months to
be 95% and the vaccine efficacy at 10 months to be 95%, 50%, or 0%.
We considered the statistically optimal design of keeping all participants on their original
treatment assignments until the end of the trial, which was set to be slightly over 10 months.
We refer to this design as Plan A, which serves as a benchmark. We also considered three
blinded crossover designs:
B. Crossover occurs over months 6-10 according to priority tier groups.
C. 20% of participants follow Plan A, and the rest follow Plan B.
D. Crossover occurs for all participants in month 6.
Both B and C are priority-tier dependent rolling crossover designs. The difference is that
under Plan B, all placebo recipients cross over to the vaccine arm, whereas under Plan C, 20%
of participants choose for altruistic reasons to stay on their original treatment assignments.
For Plan D, all placebo recipients are vaccinated over the course of a month without any
priority tiering. With blinded crossover, placebo participants receive the vaccine and vaccine
participants receive the placebo at the point of crossover, and all participants are followed
until the end of the trial, which is 10.5 months since trial initiation. The designs of these
simulation studies are detailed in Supplemental Appendix 2.
The results, based on 10,000 simulated datasets, are summarized in Table 1 and Figure
2. The proposed method yields virtually unbiased estimates of the vaccine-efficacy curves
over the 10-month period for Plans Aâ€“C in all three scenarios (95%, 50%, 0%) of long-term

4

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

vaccine efficacy; it also yields accurate variance estimates, such that the confidence intervals
have proper coverage probabilities. When vaccine efficacy is constant over time, the standard
errors for the estimates of vaccine efficacy under Plans B and C are slightly lower than those
of Plan A. When vaccine efficacy wanes over time, the standard errors for the estimates of
5-month vaccine efficacy under Plans B and C are also slightly lower than those of Plan A;
however, the standard errors for the estimates of 10-month vaccine efficacy under Plans B
and C are higher than those of Plan A, with the standard errors being slightly lower under
Plan C than under Plan B. Under Plan D, the estimates of 10-month vaccine efficacy are
slightly biased, with high standard errors; these results are not surprising, because under
this plan, the number of unvaccinated participants diminishes rapidly after month 6.
We also evaluated the performance of the standard Cox regression,16âˆ’17 with vaccine
status as a potentially time-dependent covariate. Because it estimates an overall vaccine
efficacy among individuals who have been vaccinated for different amounts of time, this
method over-estimates long-term vaccine efficacy when vaccine efficacy decreases over time,
although the estimation is unbiased when vaccine efficacy is constant over time.
We conducted a second series of simulation studies by considering unblinded crossover,
under which participants are notified of their original treatment assignments and placebo
recipients are vaccinated soon after. In this series, crossover occurs at the same time as in
Plans Bâ€“D but is unblinded; we refer to these three plans as Bâ€™â€“Dâ€™ (Supplementary Appendix
2). Because vaccine recipients may engage in riskier behavior upon unblinding, we discarded
the data collected after unblinding for both the vaccine and placebo groups by censoring
each participantâ€™s time to disease at their time of unblinding visit; the resulting analysis
avoids any bias due to behavioral confounding.
The results for the second series of simulation studies, based on 10,000 simulated datasets,
are summarized in Table 2 and Figure 3. The proposed method yields unbiased estimates of
the vaccine-efficacy curves under Plans Bâ€™ and Câ€™, but with much higher standard errors for
estimates of long-term vaccine efficacy than under Plans B and C; the standard errors can
be accurately estimated, although only up to month 10. Under Plan Dâ€™, the estimates of
5

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

5-month vaccine efficacy are unbiased; however, the estimates of 10-month vaccine efficacy
are biased, especially when vaccine efficacy wanes over time. Naturally, long-term efficacy
cannot be estimated as well under unblinded crossover as under blinded crossover because of
limited blinded follow-up data, especially under Plan Dâ€™. Of note, the bias of the standard
Cox regression in estimating waning vaccine efficacy is more severe under unblinded crossover
than under blinded crossover.
Figure 4 displays the analysis results produced by the proposed methods for one of the
trials simulated with 50% 10-month vaccine efficacy. The estimates of vaccine efficacy are
close to the truth, and the 95% confidence intervals cover the truth mostly â€” up to the end
of blinded follow-up. In terms of estimating long-term vaccine efficacy, Plan C is nearly as
good as Plan A and is slightly better than Plan B, which is better than Plan D; Plans B, C,
and D are substantially better than Plans Bâ€™, Câ€™, and Dâ€™, respectively.
Discussion
For a preventive COVID-19 vaccine to be administered to millions of people, including
healthy individuals, its safety and efficacy must be demonstrated in a clear and compelling
manner. Although preliminary results from ongoing phase 3 clinical trials have revealed
higher than expected efficacy of COVID-19 vaccines,4âˆ’6 additional follow-up is required to
assess long-term efficacy and safety. Indeed, FDA does not consider issuance of an EUA, in
and of itself, as grounds for stopping blinded follow-up in an ongoing clinical trial.15
We recommend the rolling crossover design, which allows placebo recipients to be vaccinated in a timely manner while still making it possible to assess long-term safety and efficacy.
The standard Cox regression seriously over-estimates long-term vaccine efficacy when vaccine efficacy wanes over time, as shown in our simulation studies. We have developed a
valid and efficient approach to evaluate the potential waning efficacy of a COVID-19 vaccine. The estimated curve of time-varying vaccine efficacy can be used to determine when
a booster vaccination is needed to sustain protection; this information is also an important
input parameter in mathematical modeling of the population impact of COVID-19 vaccines.
6

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

To ensure high-quality follow-up data, crossover should ideally be blinded, with placebo
participants receiving vaccine and vaccine participants receiving placebo at the time of
crossover. Unblinded crossover has practical benefits over blinded crossover: it reduces
operational complexity and trial cost. However, unblinding can lead to differential exposure
to SARS-CoV-2 between the original vaccinees and the placebo crossovers, which in turn
can bias the estimation of vaccine efficacy.
This bias can be avoided by analyzing only the blinded follow-up data. However, discarding the unblinded follow-up data may substantially reduce the precision in estimating
long-term vaccine efficacy. We suggest to estimate vaccine efficacy in two ways, one using
all follow-up data and one using only blinded follow-up data, and compare the two results.
Another solution is to apply our methods to all follow-up data but perform a sensitivity
analysis to assess the robustness of the results to potential unmeasured confounding caused
by unblinding of trial participants. In Supplemental Appendix 3, we show how to apply a
best-practice general methodology in epidemiological research18âˆ’19 to perform this sensitivity
analysis. Specifically, we can assess how strong unmeasured confounding due to unblinding
would need to be in order to fully explain away the observed vaccine efficacy. We can also
provide a conservative estimate of vaccine efficacy that accounts for unmeasured confounding.
Recently, Follmann et al

20

advocated blinded crossover and continued follow-up of trial

participants to assess vaccine durability and potential delayed enhancement of disease. They
estimated an overall vaccine efficacy for the original vaccine arm in the post-crossover period
(after all placebo recipients have been vaccinated) by imputing the case count for a counterfactual placebo group under several assumptions: that the vaccine and placebo groups remain
balanced at the point of cross-over; that the crossover pattern and duration of follow-up in
the second period are comparable to the enrollment pattern and duration of follow-up in
the first period; and that the benefit of vaccination over time has the same profile between
the original vaccinees and the placebo crossovers. We address the issue of long-term vaccine
efficacy in a different way, using observed data to estimate the entire curve of vaccine efficacy
as a function of time elapsed since vaccination, up to the point where most participants have
7

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

been vaccinated. Our approach requires minimal assumptions and is applicable to both
blinded and unblinded crossover plans, with any length of additional follow-up.
Acknowledgments
The authors thank Yu Gu and Bridget I. Lin for assistance. This work was supported by
the National Institutes of Health grants R01 AI029168, R01 GM124104, P01 CA142538, and
UM1 AI068635.
References
1. Krause P, Fleming, TR, Longini I, et al (2020). COVID-19 vaccine trials should seek
worthwhile efficacy. Lancet, 396: 741-743.
2. Cohen MS, Corey L (2020). Combination prevention for COVID-19. Science 368: 551.
3. Corey L, Mascola JR, Fauci AS, Collins FS (2020). A strategic approach to COVID-19
vaccine R&D. Science 368: 948-50.
4. Polack FP, Thomas SJ, Kitchin N, et al (2021). Safety and efficacy of the BNT162b2
mRNA Covid-19 vaccine. New Eng J Med, 383: 2603-15.
5. Baden LR, El Sahly HM, Essink B, et al (2021). Efficacy and safety of the mRNA-1273
SARS-CoV-2 vaccine. New Eng J Med (DOI: 10.1056/NEJMoa2035389).
6. Voysey M, Clemens SAC, Madhi SA, et al (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four
randomised controlled trials in Brazil, South Africa, and the UK. Lancet, in press.
7. Xia S, Duan K, Zhang Y, et al (2020). Effect of an inactivated vaccine against SARSCoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized
clinical trials. J Am Med Ass, 324: 951-960.

8

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

8. Jackson LA, Anderson EJ, Rouphael NG, et al (2020). An mRNA vaccine against
SARS-CoV-2 â€“ Preliminary report. New Eng J Med, 383: 1920-31.
9. Folegatti PM, Ewer KJ, Aley PK, et al (2020). Safety and immunogenicity of the
ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase
1/2, single-blind, randomised controlled trial. Lancet, 396: 467-478.
10. Keech C, Albert G, Cho I, et al (2020). Phase 1-2 Trial of a SARS-CoV-2 recombinant
spike protein nanoparticle vaccine. New Eng J Med, 383: 2320-32.
11. The World Health Organization (2020). Draft landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidatevaccines (accessed December 8, 2020).
12. The World Health Organization (2020). An international randomised trial of candidate
vaccines against COVID-19. https://www.who.int/publications-detail/an-internationalrandomised-trial-of-candidate-vaccines-against-covid-19.
13. U.S. Food and Drug Administration (2020). Development and Licensure of Vaccines
to Prevent COVID-19: Guidance for Industry.
14. The World Health Organization (2020). WHO target product profiles for COVID19 vaccines. https://www.who.int/who-documents-detail/who-target-productprofilesfor-covid-19-vaccines.
15. U.S. Food and Drug Administration (2020). Emergency Use Authorization for Vaccines
to Prevent COVID-19: Guidance for Industry. https://www.fda.gov/media/142749/download.
16. Cox DR (1972). Regression models and life-tables. J Roy Stat Soc B, 34: 187-202.
17. Kalbfleisch JD, Prentice RL (2011). The Statistical Analysis of Failure Time Data, 2nd
Ed. John Wiley & Sons.

9

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

18. VanderWeele TJ, Ding P (2017). Sensitivity analysis in observational research: introducing the E-value. Ann Int Med, 167: 268-74.
19. Ding P, VanderWeele TJ (2016). Sensitivity analysis without assumptions. Epidemiology, 27: 368.
20. Follmann D, Fintzi J, Fay MP, et al. (2020). Assessing durability of vaccine effect following blinded crossover in COVID-19 vaccine efficacy trials. https://www.medrxiv.org/
content/10.1101/2020.12.14.20248137v1

10

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Table 1. Estimation of Vaccine Efficacy (VE) by the Proposed and Standard
Methods Under No Crossover (A) and Three Blinded Crossover Plans (Bâ€“D)
in Three Scenarios of Long-Term Vaccine Efficacy

True
Scenario
(a) 5-mos VE = 95%
10-mos VE = 95%

Time

VE

Mean

SE

SEE

CP

A

5 mos
10 mos
5 mos
10 mos
5 mos
10 mos
5 mos
10 mos

95%
95%
95%
95%
95%
95%
95%
95%

95.0%
95.0%
95.0%
95.1%
95.0%
95.0%
95.0%
95.2%

0.8%
0.8%
0.7%
0.8%
0.7%
0.7%
0.8%
0.9%

0.8%
0.8%
0.7%
0.7%
0.7%
0.7%
0.8%
0.9%

95.2%
94.5%
95.1%
94.5%
95.2%
94.5%
94.8%
93.6%

5 mos
10 mos
5 mos
10 mos
5 mos
10 mos
5 mos
10 mos

95%
50%
95%
50%
95%
50%
95%
50%

95.0% 0.8% 0.8%
49.9% 4.7% 4.6%
95.0% 0.7% 0.7%
49.9% 6.4% 6.4%
95.0% 0.7% 0.7%
49.9% 5.7% 5.6%
95.0% 0.8% 0.8%
49.3% 10.0% 10.0%

95.3%
95.0%
95.0%
95.3%
95.2%
95.2%
94.7%
95.1%

5 mos
10 mos
5 mos
10 mos
5 mos
10 mos
5 mos
10 mos

95%
0%
95%
0%
95%
0%
95%
0%

95.0% 0.8% 0.8% 95.2%
-0.2% 8.1% 8.0% 95.1%
95.0% 0.7% 0.7% 95.2%
-0.3% 11.5% 11.6% 94.8%
95.0% 0.7% 0.7% 95.3%
-0.4% 10.3% 10.2% 94.6%
95.0% 0.8% 0.8% 94.6%
-1.4% 18.8% 18.7% 95.2%

C
D

A
B
C
D

(c) 5-mos VE = 95%
10-mos VE = 0%

Standard

Plan

B

(b) 5-mos VE = 95%
10-mos VE = 50%

Proposed method

A
B
C
D

Mean

SE

95.0% 0.6%
95.0% 0.6%
95.0% 0.6%
95.0% 0.7%

73.5% 1.6%
84.2% 1.0%
81.2% 1.1%
92.8% 0.8%

54.3% 2.3%
77.0% 1.2%
71.0% 1.4%
91.5% 0.8%

Note: Mean and SE denote the mean and standard error of the estimator for vaccine efficacy, SEE denotes the mean of the standard error estimator, and CP denotes the coverage
probability of the 95% confidence interval.

11

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Table 2. Estimation of Vaccine Efficacy (VE) by the Proposed and Standard
Methods Under Three Unblinded Crossover Plans (Bâ€™â€“Dâ€™) in Three Scenarios
of Long-Term Vaccine Efficacy

True
Scenario
(a) 5-mos VE = 95%

Time

VE

Mean

SE

SEE

Bâ€™

5 mos
8 mos
10 mos
5 mos
8 mos
10 mos
5 mos
8 mos
10 mos

95%
95%
95%
95%
95%
95%
95%
95%
95%

95.0%
95.0%
95.1%
95.0%
95.0%
94.9%
95.0%
96.3%
97.0%

0.9%
0.9%
2.0%
0.9%
0.9%
7.1%
1.0%
1.3%
1.1%

0.9%
0.9%
1.3%
0.9%
0.9%
1.5%
1.0%
0.9%
0.7%

95.3%
94.0%
85.0% 95.0% 0.8%
95.1%
94.2%
83.9% 95.0% 0.8%
94.6%
65.1%
29.7% 95.0% 1.0%

5 mos
8 mos
10 mos
5 mos
8 mos
10 mos
5 mos
8 mos
10 mos

95%
81%
50%
95%
81%
50%
95%
81%
50%

95.0% 0.9% 0.9%
80.8% 2.8% 2.8%
52.1% 21.4% 14.3%
95.0% 0.9% 0.9%
80.8% 2.8% 2.8%
50.1% 20.6% 14.7%
95.0% 1.2% 1.1%
94.2% 2.3% 1.7%
95.4% 1.9% 1.4%

95.1%
95.1%
86.4% 88.2% 1.2%
95.3%
94.9%
88.1% 88.1% 1.3%
94.8%
5.2%
0.4% 95.5% 0.9%

5 mos
8 mos
10 mos
5 mos
8 mos
10 mos
5 mos
8 mos
10 mos

95%
71%
0%
95%
71%
0%
95%
71%
0%

95.0% 0.9% 0.9% 95.1%
71.1% 3.8% 3.9% 95.2%
3.3% 34.7% 26.0% 88.5% 83.4% 1.4%
95.0% 0.9% 0.9% 95.2%
71.0% 3.8% 3.7% 94.8%
-0.5% 35.2% 26.1% 89.8% 83.0% 1.5%
95.0% 1.2% 1.2% 94.9%
93.3% 3.0% 2.1% 3.3%
94.7% 2.4% 1.7% 0.2% 95.5% 0.9%

Câ€™

Dâ€™

Bâ€™

10-mos VE = 50%
Câ€™

Dâ€™

(c) 5-mos VE = 95%

Standard

Plan

10-mos VE = 95%

(b) 5-mos VE = 95%

Proposed method

Bâ€™

10-mos VE = 0%
Câ€™

Dâ€™

CP

Mean

SE

Note: Mean and SE denote the mean and standard error of the estimator for vaccine efficacy, SEE denotes the mean of the standard error estimator, and CP denotes the coverage
probability of the 95% confidence interval.

12

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Figure 1. Possible timeline for a phase 3 COVID-19 vaccine trial.

13

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

(a) VE(5 months)=95%, VE(10 months)=95%

Vaccine efficacy

100%

95%

90%

True

Plan A

Plan B

Plan C

Plan D

85%
1

2

3

4

5

6

7

8

9

10

9

10

9

10

Time since vaccination (in months)

(b) VE(5 months)=95%, VE(10 months)=50%
100%

Vaccine efficacy

80%

60%

40%

20%
True

Plan A

Plan B

Plan C

Plan D

0%
1

2

3

4

5

6

7

8

Time since vaccination (in months)

(c) VE(5 months)=95%, VE(10 months)=0%

Vaccine efficacy

100%

50%

0%

True

Plan A

Plan B

Plan C

Plan D

âˆ’50%
1

2

3

4

5

6

7

8

Time since vaccination (in months)

Figure 2. Proposed estimates of vaccine efficacy under no crossover and three
blinded crossover plans in three scenarios of long-term vaccine efficacy.

14

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

(a) VE(5 months)=95%, VE(10 months)=95%
100%

Vaccine efficacy

90%

80%

70%

True

Plan B'

Plan C'

Plan D'

60%
1

2

3

4

5

6

7

8

9

10

9

10

9

10

Time since vaccination (in months)

(b) VE(5 months)=95%, VE(10 months)=50%

Vaccine efficacy

100%

50%

0%

True

Plan B'

Plan C'

Plan D'

âˆ’50%
1

2

3

4

5

6

7

8

Time since vaccination (in months)

(c) VE(5 months)=95%, VE(10 months)=0%
100%

Vaccine efficacy

50%

0%

âˆ’50%

True

Plan B'

Plan C'

Plan D'

âˆ’100%
1

2

3

4

5

6

7

8

Time since vaccination (in months)

Figure 3. Proposed estimates of vaccine efficacy under three unblinded crossover
plans in three scenarios of long-term vaccine efficacy.

15

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Plan B
100%

90%

90%

Vaccine efficacy

Vaccine efficacy

Plan A
100%

80%
70%
60%
50%
40%
30%

80%
70%
60%
50%
40%
30%

2

3

4

5

6

7

8

9

10

2

Time since vaccination (in months)

100%

90%

90%

80%
70%
60%
50%
40%
30%

5

6

7

8

9

10

80%
70%
60%
50%
40%
30%

2

3

4

5

6

7

8

9

10

2

Time since vaccination (in months)

3

4

5

6

7

8

9

10

Time since vaccination (in months)

Plan A

Plan B'

100%

100%

90%

90%

Vaccine efficacy

Vaccine efficacy

4

Plan D

100%

Vaccine efficacy

Vaccine efficacy

Plan C

80%
70%
60%
50%
40%
30%

80%
70%
60%
50%
40%
30%

2

3

4

5

6

7

8

9

10

2

Time since vaccination (in months)

3

4

5

6

7

8

9

10

Time since vaccination (in months)

Plan C'

Plan D'

100%

100%

90%

90%

Vaccine efficacy

Vaccine efficacy

3

Time since vaccination (in months)

80%
70%
60%
50%
40%
30%

80%
70%
60%
50%
40%
30%

2

3

4

5

6

7

8

9

10

2

Time since vaccination (in months)

3

4

5

6

7

8

9

10

Time since vaccination (in months)

Figure 4. Estimation of vaccine efficacy in a clinical trial with no crossover (A),
three blinded crossover (Bâ€“D), and three unblinded crossover (Bâ€™â€“Dâ€™): the black
curve pertains to the true value, the red curve to the proposed estimate, and
the green curves to the 95% confidence intervals.
16

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Supplemental Appendix
1. Estimation of Vaccine Efficacy
Let T and S denote the time to symptomatic COVID-19 and the time to vaccination, respectively; both times are measured in days from the start of the clinical trial. In addition,
let X denote baseline risk factors (e.g., age, occupation, comorbidities). We specify that the
hazard function of T is related to S and X through a Cox proportional hazards model with
a time-dependent regression coefficient
Î»(t|S, X) = Î»0 (t)v(t âˆ’ S)I(t>S) eÎ²

TX

,

(1)

where Î»0 (Â·) is an arbitrary baseline hazard function, v(Â·) is a positive function characterizing
the time-varying effect of vaccination, Î² is a set of regression parameters representing the
effects of baseline risk factors, and I(Â·) is the indicator function. Under this formulation, the
effect of vaccine on the risk of disease depends on the time elapsed since vaccination, but
not on the specific date of vaccination or on the baseline risk factors.
One may define the t-day vaccine efficacy (VE) as the proportionate reduction in the
cumulative incidence of disease at time t for individuals who have been vaccinated for t
days:
Rt
T
1 âˆ’ exp{âˆ’eÎ² X 0 v(u)Î»0 (u)du}
Pr(T â‰¤ t|S = 0, X)
=1âˆ’
,
V E(t) = 1 âˆ’
Rt
Pr(T â‰¤ t|S > t, X)
1 âˆ’ exp{âˆ’eÎ² T X 0 Î»0 (u)du}
which is approximately
Rt
1âˆ’

0

v(u)Î»0 (u)du
Rt
Î» (u)du
0 0

for rare disease. If Î»0 (Â·) is approximately constant, then
V E(t) = 1 âˆ’ V (t)/t,
where
Z

t

V (t) =

v(u)du.
0

For simplicity, we define the time-varying vaccine efficacy by equation (2).
17

(2)

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Suppose that the clinical trial enrolls a total of n participants. For i = 1, . . . , n, let Ri ,
Ti , Si , Ci , and Xi denote the entry time, the time to symptomatic COVID-19, the time to
vaccination, the time to loss to follow-up, and the baseline risk factors for the ith participant.
The data consist of (Ri , Yi , âˆ†i , Di , Di Si , Xi ) (i = 1, . . . , n), where Yi = min(Ti , Ci ), âˆ†i =
I(Ti â‰¤ Ci ), and Di = I(Si â‰¤ Yi ).
We assume that (Ri , Si , Ci ) are independent of Ti conditional on Xi . The likelihood takes
the form
n n
oâˆ†i
Y
T
Î»0 (Yi )eÎ² Xi
v(Yei )Di âˆ†i
i=1



Z
Î² T Xi
Ã— exp âˆ’e
(1 âˆ’ Di )

Yi

Z

Si

Î»0 (t)dt + Di

Ri

Z
Î»0 (t)dt +

Ri

Î»0 (Yi )e

Yiâˆ—


Î»0 (t)dt

Ri

i=1

Ã—


Î»0 (t)dV (t âˆ’ Si )

Si


Z
n n
o(1âˆ’Di )âˆ†i
Y
Î² T Xi
Î² T Xi
Î»0 (Yi )e
exp âˆ’e
=
n

Yi

Î² T Xi


Z
o âˆ†i
TX
Î²
i
v(Yei )
exp âˆ’e

Yi

Di
,
Î»0 (t)dV (t âˆ’ Si )

Si

where Yei = Yi âˆ’ Si , and Yiâˆ— = (1 âˆ’ Di )Yi + Di Si = min(Yi , Si ). We approximate log Î»0 (t)
P
through splines with m basis functions, B1 (t), . . . , Bm (t), such that log Î»0 (t) â‰ˆ m
k=1 Î³k Bk (t).
Let Î¸ = (Î², Î³1 , . . . , Î³m )T , and Zi (t) = [Xi , B1 (t), . . . , Bm (t)]T . We perform the nonparametric
maximum likelihood estimation,1 in which V (Â·) is treated as a step function jumping at the
time points Yei with Di = âˆ†i = 1. Thus, we maximize the objective function
n
Y
i=1

 Z
(1âˆ’Di )âˆ†i Î¸T Zi (Yi )
exp âˆ’
e

Yiâˆ—

eÎ¸

T Z (t)
i

dt

 "

( Z

âˆ†
i
T
eÎ¸ Zi (Yi ) V {Yei }
exp âˆ’

Ri

Yei

)#Di
eÎ¸

T Z (t+S )
i
i

dV (t)

0

(3)
where V {t} is the jump size of V (Â·) at t.
We first maximize the objective function in (3) for fixed Î¸ to yield
n
X
Di âˆ†i I(Yei â‰¤ t)
V (t) =
.
S (0) (Î¸; Yei )

(4)

i=1

Here and in the sequel, S (k) (Î¸; y) =

Pn

j=1

T
Dj I(Yej â‰¥ y)eÎ¸ Zj (y+Sj ) Zj (y +Sj )âŠ—k , where aâŠ—0 = 1,

aâŠ—1 = a, and aâŠ—2 = aaT for a column vector a. After plugging (4) into (3), we obtain the

18

,

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

profile likelihood for Î¸. Differentiating the profile log-likelihood with respect to Î¸ yields the
estimating function
Z
n 
X
(1 âˆ’ Di )âˆ†i Zi (Yi ) âˆ’

Yiâˆ—

e

Î¸T Z

i (t)


Zi (t)dt +

Ri

i=1

n
X

(
Di âˆ†i

i=1

S (1) (Î¸; Yei )
Zi (Yi ) âˆ’
S (0) (Î¸; Yei )

)
.

b Replacing Î¸ in (4) by Î¸b yields the estimator of V (t)
Denote the resulting estimator of Î¸ by Î¸.
Vb (t) =

n
X
Di âˆ†i I(Yei â‰¤ t)
,
b Yei )
S (0) (Î¸;
i=1

which is reminiscent of the Breslow estimator2 for the cumulative baseline hazard function
under the standard Cox model. We then estimate V E(t) through equation (2).
Using counting-process martingale theory and other mathematical arguments,3âˆ’4 we can
show that Vb (t) is consistent and asymptotically normal. In addition, the variance of Vb (t)
P
can be consistently estimated by nâˆ’1 ni=1 Wi (t)2 , where
"
#
n
bT
e
âˆ†i I(Yei â‰¤ t) X Dj âˆ†j I{Yej â‰¤ min(t, Yei )}eÎ¸ Zi (Yj +Si )
Wi (t) = Di
âˆ’
b Yei )
b Yej )2
S (0) (Î¸;
S (0) (Î¸;
j=1

âˆ’

n
X
b Yej )T
Dj âˆ†j I(Yej â‰¤ t)S (1) (Î¸;
Qi ,
b Yej )2
S (0) (Î¸;
j=1

and
)#âˆ’1
(1) b e âŠ—2
b
e
S (Î¸; Yi ) S (Î¸; Yi )
bT
âˆ’
Qi =
eÎ¸ Zi (t) Zi (t)âŠ—2 dt +
Di âˆ†i
b Yei )
b Yei )2
S (0) (Î¸;
S (0) (Î¸;
i=1
i=1 Ri
(
"
)
Z Yiâˆ—
(1) b e
S
(
Î¸;
Y
)
T
b
i
Ã— (1 âˆ’ Di )âˆ†i Zi (Yi ) âˆ’
eÎ¸ Zi (t) Zi (t)dt + Di âˆ†i Zi (Yi ) âˆ’
(0)
b
e
S (Î¸; Yi )
Ri
(
)#
n
bT
e
(1) b e
X
Dj âˆ†j I(Yei â‰¥ Yej )eÎ¸ Zi (Yj +Si )
S
(
Î¸;
Y
)
j
âˆ’
Zi (Yej + Si ) âˆ’
.
(0) (Î¸;
b Yej )
b Yej )
S
S (0) (Î¸;
j=1
"

n Z
X

Yiâˆ—

n
X

(

(2)

These results can be used to construct confidence intervals for V E(t). Specifically, we first
construct the confidence intervals for log{V (t)} and then transform them to V E(t). We
can also show the convergence of Vb (Â·) to a Gaussian process and construct simultaneous
confidence bands for V E(Â·).4
We have defined vaccine efficacy in terms of reduction in the cumulative incidence of
disease. An alternative definition is reduction in the risk of disease.5 Specifically, we define
19

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

the vaccine efficacy at time t by the proportionate reduction in the hazard rate at time t,
i.e., ve(t) = 1 âˆ’ v(t). We refer to V E(t) as t-day vaccine efficacy and to ve(t) as day-t
vaccine efficacy, the former pertaining to cumulative vaccine effect and the latter to instantaneous vaccine effect. If the hazard ratio is constant over time, then the two definitions are
equivalent. If the hazard ratio increases over time, then V E(t) is higher than ve(t). We can
estimate v(t) and thus ve(t) through kernel smoothing of Vb (t).6

2. Designs of Simulation Studies
We assumed that 40,000 participants entered the study at a constant rate over four months,
i.e., R âˆ¼ Uniform(0, 4). We created a composite baseline risk score X, which takes values 1,
2, 3, 4, and 5 with equal probability. At study entry, half of the participants were assigned
to vaccine and half to placebo. The statistically optimal design would be to maintain the
original vaccine and placebo groups until the end of the study, which was set to be 10.5
months. We refer to this design as Plan A. We also considered three blinded crossover
designs, under which placebo participants receive vaccine and vaccine participants receive
placebo at the time of crossover and all participants are followed until the end of the study:
Plan B. Crossover occurs at month (11 âˆ’ X + G), where G follows the exponential
distribution with mean of 0.5.
Plan C. 20% of participants follow Plan A and 80% follow Plan B.
Plan D. Crossover occurs at month 6 + G, where G follows the exponential distribution
with mean of 0.5.
Plan C mimics a scenario where all participants are offered the option of crossover but a
small percentage (20%) choose to stay on the original assignments for the sake of science.
In addition, we considered three unblinded crossover designs:
Plan Bâ€™. Crossover occurs at month (11.5 âˆ’ X).
Plan Câ€™. 20% of participants follow Plan A and 80% follow Plan Bâ€™.
Plan Dâ€™. Crossover occurs at month 6.5.

20

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Under unblinded crossover, participants are notified of their original assignments at the time
of crossover, and placebo participants receive the vaccine soon after. In practice, only placebo
participants would cross over, since there is no need to give placebo to vaccine recipients
after unblinding. In Plans Bâ€™â€“Dâ€™, the time of crossover is the time of unblinding rather than
the time when placebo participants actually receive the vaccine. Because participants might
change their behavior upon discovering their original treatment assignments, we discarded
the follow-up data collected after unblinding by censoring each participantâ€™s time to disease
at their time of unblinding. This strategy avoids bias due to behavioral confounding, at the
cost of reduced statistical efficiency.
We generated the event time T from model (1) with Î³ = 0.2,
log Î»0 (t) = âˆ’5.93 + 0.1t âˆ’ 0.3(t âˆ’ 7)+ ,
and
log v(t) = a + bt, t > 0,
where a and b were chosen to achieve the desired VE values at 5 and 10 months. We censored
T at the time of unblinding crossover under Plans Bâ€™â€“Dâ€™.
For each simulated dataset, we estimated log Î»0 (t) using a piece-wise constant function
with 20 pieces placed at the equal quantiles of the observed event times. We then estimated
V (t) using the proposed method and estimated V E(t) according to equation (2). For comparisons, we also fit a Cox model that includes X and time-dependent covariate I(S < t) to
estimate VE by 1 minus the estimated hazard ratio of the time-dependent covariate.

3. Sensitivity Analysis
We suggest reporting the E-value7 as a summary measure of the evidence against the null
hypothesis H0 : V E(t) â‰¤ 0. The E-value is the minimum strength of association on the risk
ratio scale, i.e, RR(t) = 1 âˆ’ V E(t), that an unmeasured confounder would need to have
with both vaccination status and disease outcome in order to fully explain away a specific

21

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

d be the estimate of RR(t), and let U L(t) be the upper
observed vaccine efficacy. Let RR(t)
d is given by
limit of the 95% confidence interval for RR(t). Then the E-value for RR(t)
q
d
1 + 1 âˆ’ RR(t)
e(t) =
,
d
RR(t)
d < 1. In addition, the E-value for U L(t) is computed as 1 if U L(t) â‰¥ 1
provided that RR(t)
and as
eU L (t) =

1+

p

1 âˆ’ U L(t)
U L(t)

otherwise. E-values near one suggest weak support for a causal inference, and greater Evalues provide increasing evidence for causality.
d
Suppose, for example, that RR(t)
= 0.50, with 95% confidence interval (0.08, 0.75).
d
Then e(t) = 3.4, meaning that the result of RR(t)
being less than one could be explained
away by an unmeasured confounder associated with both vaccination status and disease by
a risk ratio of 3.4-fold each after accounting for the vector X of measured confounders, but
not by a weaker unmeasured confounder. In addition, eU L (t) = 2.5, which is the strength
of unmeasured confounding at which statistical significance for V E(t) > 0 would be lost.
These two E-values judge how confident we can be that V E(t) truly exceeds 0, accounting
for potential unmeasured confounding due to unblinding as well as for sampling variability.
We can provide a conservative estimate of V E(t) that accounts for potential unmeasured
confounding.8 Let RRU D (t) be the maximum risk ratio for disease when comparing any
two categories of the unmeasured confounder U , within either the vaccinated group or the
unvaccinated group, conditional on the vector X of observed covariates, and let RREU (t)
be the maximum risk ratio for any specific level of the unmeasured confounder U when
comparing the vaccinated and unvaccinated individuals. Define the bias or bounding factor
B(t) =

RRU D (t)RREU (t)
.
RRU D (t) + RREU (t) âˆ’ 1

d
Then a conservative (lower bound) estimate of the vaccine efficacy is given by 1âˆ’ RR(t)B(t),
and a conservative confidence interval is obtained by multiplying the lower and upper limits
of the confidence interval for RR(t) by B(t).
22

medRxiv preprint doi: https://doi.org/10.1101/2021.01.13.21249779; this version posted January 21, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

References
1. Kalbfleisch JD, Prentice RL (2011). The Statistical Analysis of Failure Time Data, 2nd
Ed. John Wiley & Sons.
2. Breslow NE (1972). Discussion of the paper by D. R. Cox. J Roy Stat Soc B, 34:
216-217.
3. Fleming TR, Harrington DP (1991). Counting Processes and Survival Analysis. John
Wiley & Sons.
4. Lin DY, Fleming TR, Wei LJ (1994). Confidence bands for survival curves under the
proportional hazards model. Biometrika, 81: 73-81.
5. Durham LK, Longini Jr IM, Halloran ME, Clemens JD, Azhar N, Rao M (1998).
Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines.
American Journal of Epidemiology, 147: 948-959.
6. Ramlau-Hansen H (1983). Smoothing counting process intensities by means of kernel
functions. The Annals of Statistics, 11: 453-466.
7. VanderWeele TJ, Ding P (2017). Sensitivity analysis in observational research: introducing the E-value. Ann Int Med, 167: 268-74.
8. Ding P, VanderWeele TJ (2016). Sensitivity analysis without assumptions. Epidemiology, 27: 368.

23

